Quick Answer
Prelude Therapeutics Inc reported Total Revenue of $12.14 million for fiscal year 2025.
Prelude Therapeutics Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $12.14M +73.4% |
$7.00M | — | — | — | — |
| Revenue (ASC 606) | $12.14M +73.4% |
$7.00M | — | — | — | — |
| Net Income | -$99.50M +21.8% |
-$127.17M -4.4% |
-$121.83M -5.5% |
-$115.44M -3.4% |
-$111.69M -96.2% |
-$56.93M -106.5% |
| Diluted EPS | -$1.29 +23.2% |
-$1.68 +16.8% |
-$2.02 +17.2% |
-$2.44 -0.4% |
-$2.43 | — |
| Total Assets | $141.31M -19.5% |
$175.51M -36.8% |
$277.67M +25.9% |
$220.50M -27.7% |
$305.10M +36.5% |
$223.59M +922.3% |
| Cash and Equivalents | $35.26M +182.6% |
$12.47M -50.7% |
$25.29M -17.4% |
$30.61M -3.8% |
$31.83M -85.4% |
$218.31M +1056.4% |
| Stockholders Equity | $68.64M -47.8% |
$131.46M -44.6% |
$237.09M +21.3% |
$195.44M -31.6% |
$285.90M +34.7% |
$212.18M +529.4% |
| R&D Expense | $94.30M -20.1% |
$118.00M +14.1% |
$103.39M +11.3% |
$92.89M +7.0% |
$86.78M +80.1% |
$48.18M +98.4% |
| Operating Income | -$104.57M +25.2% |
-$139.71M -5.6% |
-$132.28M -7.1% |
-$123.54M -8.6% |
-$113.73M -93.5% |
-$58.76M -109.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $6.50M | +116.7% | +116.7% |
| Revenue (ASC 606) | September 30, 2025 | $6.50M | +116.7% | +116.7% |
| Net Income | September 30, 2025 | -$19.73M | +38.9% | +36.8% |
| Diluted EPS | September 30, 2025 | -$0.26 | +39.5% | +36.6% |
| Total Assets | September 30, 2025 | $94.75M | -52.0% | -17.5% |
| Cash and Equivalents | September 30, 2025 | $47.53M | +326.9% | +84.6% |
| Stockholders Equity | September 30, 2025 | $58.53M | -62.6% | -22.8% |
| R&D Expense | September 30, 2025 | $21.71M | -26.3% | -15.8% |
| Operating Income | September 30, 2025 | -$20.42M | +40.6% | +36.6% |
- Prelude Therapeutics Inc reported Total Revenue of $12.14 million for fiscal year 2025.
- Prelude Therapeutics Inc showed an increase of +73.4% in Total Revenue compared to the prior fiscal year.
- Prelude Therapeutics Inc reported Revenue (ASC 606) of $12.14 million for fiscal year 2025.
- Prelude Therapeutics Inc showed an increase of +73.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Prelude Therapeutics Inc reported Net Income of -$99.50 million for fiscal year 2025.
- Prelude Therapeutics Inc showed an increase of +21.8% in Net Income compared to the prior fiscal year.
- Prelude Therapeutics Inc reported Diluted EPS of $1.29 per share (loss) for fiscal year 2025.
- Prelude Therapeutics Inc showed an increase of +23.2% in Diluted EPS compared to the prior fiscal year.
- Prelude Therapeutics Inc reported Total Assets of $141.31 million for fiscal year 2025.
- Prelude Therapeutics Inc showed a decrease of -19.5% in Total Assets compared to the prior fiscal year.
- Prelude Therapeutics Inc reported Cash and Equivalents of $35.26 million for fiscal year 2025.
- Prelude Therapeutics Inc showed an increase of +182.6% in Cash and Equivalents compared to the prior fiscal year.
- Prelude Therapeutics Inc reported Stockholders Equity of $68.64 million for fiscal year 2025.
- Prelude Therapeutics Inc showed a decrease of -47.8% in Stockholders Equity compared to the prior fiscal year.
- Prelude Therapeutics Inc reported R&D Expense of $94.30 million for fiscal year 2025.
- Prelude Therapeutics Inc showed a decrease of -20.1% in R&D Expense compared to the prior fiscal year.
- Prelude Therapeutics Inc reported Operating Income of -$104.57 million for fiscal year 2025.
- Prelude Therapeutics Inc showed an increase of +25.2% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: